cyclic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-18. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
| Property | Value | Notes |
|---|---|---|
| Solid-state storage | -20 degrees Celsius or lower | Desiccated and protected from light |
| Solution stability | Short and method-dependent | Confirm by stability testing |
| Purity assessment | Reversed-phase HPLC | Reported as area percent |
| Identity confirmation | LC-MS or comparable method | Mass match against expected value |
| Common synonyms | MT-II; melanotan II | Informal and catalogue names |
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
2024 – David Perlman Memorial Award, American Chemical Society, Biochemical Technology. 2024 – Founder Award, Kendall Square Association. 2024 – American Association for Cancer Research Academy, Fellow. 2023 – Australian Academy of Technological Science & Engineering, Fellow. 2021 – Outstanding Scientist Award, AAISCR Cancer Research Annual Meeting. 2019 – Honorary Degree, DSc (Medicine) University of London – Institute Cancer Research. 2017 – Catalyst Award, Science Club for Girls. 2017 – Innovation at the Intersection Award, Xconomy Awards, Biotech Week Boston. 2017 – Honorary Degree, Doctorate Utrecht University, the Netherlands. 2017 – AIMBE STEM Award, American Institute for Medical and Biological Engineering. 2015 – 20th Heinz Award for Technology, Heinz Family Foundation. 2015 – American Academy of Arts and Sciences, Fellow. 2014 – Lemelson-MIT Prize, Lemelson-MIT Program. 2014 – Pioneers of Miniaturization Prize, Lab on a Chip Lectureship at MicroTAS. 2011 – Massachusetts Academy of Sciences, Fellow. 2011 – Biomedical Engineering Society, Fellow. 2011 – Brown Engineering Alumni Medal, Brown University School of Engineering. 2011 – Thomas A. McMahon Mentoring Award, MIT, Health Sciences & Technology. 2010 – John J. and Dorothy Wilson Professor, MIT, HST & EECS, Endowed Chair. 2010 – Young Investigator Award, American College of Clinical Pharmacology. 2009 – American Society for Clinical Investigation, Fellow. 2005 – American Institute for Medical and Biological Engineering, Fellow. 2003 – Y.C. Fung Young Investigator Award, American Society of Mechanical Engineers.
=== Specific diseases === A common cause for hyperprolactinemia is prolactinomas and other tumors arising near the pituitary. These adjacent tumors, such as those that cause acromegaly, can physically compress the pituitary stalk and block the flow of dopamine from the hypothalamus to the pituitary gland, causing prolactin levels to increase. Other causes include chronic kidney failure, hypothyroidism, liver cirrhosis, bronchogenic carcinoma and sarcoidosis. Hyperprolactinemia develops in one-third of individuals with chronic kidney disease due to impaired renal clearance and regulation. Some women with polyendocrine metabolic ovarian syndrome may have mildly elevated prolactin levels. Premenstrual dysphoric disorder appears to be also correlated with elevated prolactin levels. In men, hyperprolactinemia leads to hypoactive sexual desire and, occasionally, erectile dysfunction. However, the link between erectile dysfunction and prolactin levels is not conclusive. When prolactin levels return to normal in these individuals, sexual desire fully recovers; however, erectile dysfunction only partially recovers. Nonpuerperal mastitis may induce transient hyperprolactinemia (neurogenic hyperprolactinemia) of about three weeks' duration; conversely, hyperprolactinemia may contribute to nonpuerperal mastitis. Some inflammatory conditions, such as rheumatoid arthritis and systemic lupus erythematosus, are also linked to higher prolactin levels in certain regions.
A table or chart of nuclides is a two-dimensional graph of isotopes of the chemical elements, in which one axis represents the number of neutrons (symbol N) and the other represents the number of protons (atomic number, symbol Z) in the atomic nucleus. Each point plotted on the graph thus represents a nuclide of a known or hypothetical element. This system of ordering nuclides can offer a greater insight into the characteristics of isotopes than the better-known periodic table, which shows only elements and not their isotopes. The chart of the nuclides is also known as the Segrè chart, after Italian physicist Emilio Segrè.
=== Applications in marketing and advertising === Industry standards now cover AI agents that plan, negotiate, and buy digital media. In 2026, the technology arm of the Interactive Advertising Bureau, IAB Tech Lab, published the Agentic Advertising Management Protocols (AAMP), an open framework for agents that discover inventory, negotiate, and complete media transactions on behalf of buyers and sellers. This differs from platform-native automation such as Google Ads Smart Bidding and Meta Advantage+, which optimize bids and delivery inside a single advertising platform. Cross-channel agents instead recommend budget changes across media, typically with a human in the loop.
== Transcript variants == Transcription of C3orf62 produces 5 alternatively spliced variants and 1 unspliced form. Of the four splice variants, two of them are protein coding, one is nonsense meditated decay, and one is a retained intron. QIAGEN denotes the following as transcription factor binding sites in the C3orf62 promoter: TFCP2, Pax-6, p53, MyoD, YY1, Ik-2, AREB6, IRF-7A3.
Sources: en.wikipedia.org
Strontium-90 (90Sr) is a radioactive isotope of strontium produced by nuclear fission, with a half-life of 28.91 years. It undergoes β− decay into 90Y (yttrium-90) with a decay energy of 546 keV. 90Sr has applications in medicine and industry and is an isotope of concern in fallout from nuclear weapons, nuclear weapons testing, and nuclear accidents.
=== Pars nervosa === Also called the neural lobe or posterior lobe, this region constitutes the majority of the posterior pituitary and is the storage site of oxytocin and vasopressin. Sometimes (incorrectly) considered synonymous with the posterior pituitary, the pars nervosa includes Herring bodies and pituicytes.
== In literature == The literary lich developed from monsters found in earlier classic sword and sorcery fiction, which is filled with powerful sorcerers who use their magic to triumph over death. Many of Clark Ashton Smith's short stories feature powerful wizards whose magic enables them to return from the dead. Several stories by Robert E. Howard, such as the novella Skull-Face (1929) and the short story "Scarlet Tears", feature undying sorcerers who retain a semblance of life through mystical means, their bodies reduced to shriveled husks with which they manage to maintain inhuman mobility and active thought. The term lich, used as an archaic word for corpse (or body), is commonly used in these stories. Ambrose Bierce's tale of possession "The Death of Halpin Frayser" features the word in its introduction, referring to a corpse. H. P. Lovecraft also used the word in "The Thing on the Doorstep" (published 1937) where the narrator refers to the corpse of his friend possessed by a sorcerer. Liches are sometimes depicted using a magical device called a phylactery to anchor their souls to the physical world so that if their body is destroyed they can rise again over and over, as long as the phylactery remains intact. Other imagery surrounding demiliches, in particular that of a jeweled skull, is drawn from the early Fritz Leiber story "Thieves' House". Gary Gygax, one of the co-creators of Dungeons & Dragons, said that he based the description of a lich included in the game on the short story "The Sword of the Sorcerer" (1969) by Gardner Fox.
Davy was not a physician, and he never administered nitrous oxide during a surgical procedure. He was, however, the first to document the analgesic effects of nitrous oxide, as well as its potential benefits in relieving pain during surgery:
Signal 1 is provided by the T-cell receptor when recognizing a specific antigen on a MHC molecule. Signal 2 comes from co-stimulatory receptors on T cell such as CD28, triggered via ligands presented on the surface of other immune cells such as CD80 and CD86. These co-stimulatory receptors are expressed only when an infection or inflammatory stimulus is detected by the innate immune system, known as a "danger signal". This two-signal system makes sure that T cells only respond to harmful stimuli (i.e. pathogens or injury) and not to self-antigens. An additional third signal is provided by cytokines, which regulate the differentiation of T cells into different subsets of effector T cells. There are a myriad of molecules involved in the complex biochemical process (called trans-membrane signaling) by which T-cell activation occurs. Below, the signaling cascade is described in detail.
Sources: en.wikipedia.org
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.
There is no single harmonised standard governing these products, and manufacturing conditions differ. Impurities may include truncated sequences, oxidation products, residual solvents, and counter-ions. Independent testing is often the only way to characterise a given lot.
Reported studies have looked at pigmentation, photoprotection, and metabolic or appetite-related endpoints in small experimental settings. Much of the evidence base is early-stage and limited in size. Questions about long-term effects and clinical relevance remain open.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.